LETTER TO THE EDITOR

Fanconi anemia gene variants in therapy-related myeloid neoplasms

Blood Cancer Journal (2015) 5, e323; doi:10.1038/bcj.2015.44; published online 3 July 2015

Therapy-related myeloid neoplasms (t-MN) include myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) occurring as a late effect of chemotherapy and/or radiotherapy for a primary malignancy or for autoimmune diseases.1–2 The incidence of this complication has been raising in the past years because of the prolonged survival and the higher number of treated patients. Still, < 5% of patients exposed to cytotoxic drugs and radiotherapy develop a t-MN, suggesting an underlying individual susceptibility. Primary malignancies most frequently associated to t-MN are breast cancer and lymphoproliferative diseases. Other recurrent clinical characteristics are presence of multiple primary neoplasms in the same individual and cancer familiarity.2 So far, higher frequency of single-nucleotide variants and radiotherapy develop a t-MN, suggesting an underlying primary malignancies most frequently associated to t-MN are breast cancer and lymphoproliferative diseases. Other recurrent clinical characteristics are presence of multiple primary neoplasms in the same individual and cancer familiarity.2 So far, higher frequency of single-nucleotide variants of detoxification and DNA-repair enzymes, alone or in association, have been reported in t-MN, but none has been validated as significant risk factor in large patient groups.3–6

The association of breast and other cancers to myeloid neoplasms is frequent in Fanconi anemia (FA), a childhood syndrome characterized by chromosomal instability, developmental abnormalities, aplastic anemia and by predisposition to cancer, particularly gyneocolological, head-neck and gastrointestinal.7–9 FA is associated to the occurrence of bi-allelic loss-of-function mutations in the family of FANC genes, comprising 16 DNA-repair genes. Mutations in FANCA, FANCC and FANCG are the most common, and account for ~ 85% of the FA patients. Less than 5% of FA patients do not appear to have mutations in these 16 genes, indicating that additional genes may be involved. Carriers of germline homozygous mutations of at least five of the sixteen FA genes, including FANCD1/BRCA2, FANCD1/BRIP1, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCI/BRIP1, FANCI/PHF9, FANCN, FANCM and RAD51C, are at a higher-risk to develop cancer.

So far, mutations in FA genes have been rarely described in hematological malignancies outside the syndromic picture of FA.10–12 We were interested in the prevalence of FA variants in t-MN following cytotoxic treatment for breast cancer and lymphoproliferative diseases, compared with de novo acute myeloid leukemia (dnAML).

We studied 37 patients with a t-MN, diagnosed at our Department of Hematology between November 1995 and January 2012. Table 1 shows patient characteristics. Median age was 63 years (range 30–78). According to the proportion of blasts, there were 19 t-MDS and 18 t-AML. Cytogenetic analysis of bone marrow mononuclear cells obtained at t-MN diagnosis revealed clonal aberrations in 24 out of 32 available samples (75%). The primary malignancy was Hodgkin lymphoma in 7 patients, non-Hodgkin lymphoma in 12 patients and breast cancer in 18 patients (associated with a second malignancy in five patients). As a control, 24 dnAML patients, of a median age of 61 years (range 40–78 years), were studied at the Istituto Seragnoli of the University of Bologna. Patients gave informed consent to the study and the protocol received approval from the local Ethical Committees.

Bone marrow mononuclear cells were separated at the time of initial t-MN diagnosis using Ficoll Gradient centrifugation (Cedarlane, ON, Canada), and DNA was extracted by using the QIAamp DNA Mini Kit (Qiagen AG, Hilden, Germany). DNA extracted from different tissues of the same individuals served as germline controls and included: lymphnode biopsies or breast specimens (neoplastic and non-neoplastic) collected at the time of the primary cancer diagnosis, buccal brush cytology or hair follicles collected at the time of t-MN or dnAML diagnosis, peripheral blood or bone marrow samples collected during follow-up of the primary malignancy or at the time of complete remission. We selected 14 Fanconi pathway genes (FANCD1/BRCA2, FANCI/BRIP1, FANCI/BRIP1, FANCI/PHF9, FANCN/PALB2, FANCO/RAD51C and FANCO/ERCC4), are at a higher-risk to develop cancer.

Table 1. Patient characteristics

| Patient characteristics       | n (range) |
|------------------------------|-----------|
| Median age (years, median, range) | 63 (30–78) |
| Sex (M/F)                     | 9/28      |
| Type of t-MN according to the WHO |           |
| AML                          | 18        |
| MDS                          | 19        |
| RA                           | 6         |
| RAEB-1                       | 4         |
| RAEB-2                       | 9         |
| Primary malignancy           |           |
| Hodgkin lymphoma             | 7         |
| Non-Hodgkin lymphoma         | 12        |
| Breast cancer                | 13        |
| Breast and another cancer    | 5         |
| Karyotype (n = 32 pts)       |           |
| Normal                       | 8         |
| Complex                      | 11        |
| Isolated Chr. 7 abnorm.      | 4         |
| Chr. 5+Chr. 7 abnorm.        | 3         |
| 11q23                        | 1         |
| Balanced translocation       | 2         |
| Other                        | 3         |
| Treatment for primary malignancy |         |
| CHT                          | 23        |
| RT                           | 1         |
| RT+CHT                       | 13        |
| Median latency between primary cytotoxic therapy and t-MN diagnosis (years) | 6 (1.3–32.5) |
| Median overall survival (months) | 8 (0.1–88) |

Abbreviations: AML, acute myeloid leukemias; CHT, chemotherapy; MDS, myelodysplastic syndromes; RA, refractory anemia; RT, radiotherapy.
Table 2. Characteristics of t-MN patients carriers of FANC variants

| UPN  | Primary tumor, age | t-MN latency, karyotype | Gene symbol and AA change | NCBI rs and/or COSMIC numbers | Control tissue |
|------|-------------------|------------------------|---------------------------|--------------------------------|----------------|
| 6531 | Breast, 57 years  | 72 months, del5q31     | FANCA L6F                 | rs189841793                     | Breast cancer and normal breast tissue |
| 3155 | NHL, 69 years     | 66 months, complex     | FANCA 590T                | Novel                          | Novel NHL biopsy |
| 5993 | HL, thyroid, 52 years | 48 months, Del7       | FANC2D T1367A             | Novel                          | HL biopsy and normal lymphnode |
| 6190 | HL, 47 years      | 208 months, Trisomy 8  | FANC2D P2565              | Novel                          | Buccal swab and hair follicle |
| 5528 | HL, 60 years      | 112 months, n.a.       | FANC2D M1023V             | Novel                          | HL biopsy |
| 2885 | Breast/ adrenal, na | na                     | FANCJ I364F FANCC L36F    | Novel                          | Not available |

Abbreviations: HL, Hodgkin lymphoma; NHL, Non-Hodgkin lymphoma; t-MN, therapy-related myeloid neoplasms. NCBI and Cosmic database variant number and the reported frequency is indicated.

hybridized to the HaloPlex probe capture library. During the hybridization process, Illumina (San Diego, CA, USA) sequencing motifs including index sequences were incorporated into the targeted fragments. The circularized target DNA-HaloPlex probe hybrids, containing bait, captured on streptavidin beads were then ligated using a DNA ligase to close nicks in the circularized HaloPlex probe-target DNA hybrids. The captured target DNA was then eluted with NaOH and amplified by PCR. The amplified target DNA was purified using AMPure XP beads (Beckman Coulter Inc, High Wycombe, UK), validated and quantified by microfluidics analysis using the 2100 Bioanalyzer (Agilent Technologies). Samples have been pooled with different indexes for multiplexed sequencing using Illumina HiSeq platform at the Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School in Singapore. Sequencing data were aligned to hg19 using the Burrows-Wheeler Aligner software. Variants were called using the Genome Analysis Toolkit (GATK, v1.0.4.333; Beckman Coulter Inc). dnaML samples were studied using 100 bp paired-end whole-exome-sequencing (HiSeq2000, Illumina). Variants were called with the Genome Analysis Toolkit (GATK).

Variants detected by NGS were confirmed by pyrosequencing or Sanger sequencing, using specifically designed oligonucleotides targeting the mutated region (Supplementary Table 1). Reagents and conditions were as recommended by the manufacturers (PyroMark Q96 ID, Diatech Pharmacogenetics, Jesi, Italy). A BLAST search on NCBI, Cosmic and UCSC databases was performed for all identified variants. The Polyphen-2 tool (genetics.bwh.harvard.edu) was consulted to define the putative effect of FA discovered variants, predicting the possible impact of the amino acid substitutions on the structure and function of the proteins. Odds ratios, with 95% confidence interval were also calculated.

FA gene variants were frequent in our t-MN patients, with 6 out of 37 (16%) carriers of at least one genomic variant, with similar prevalence in t-MN secondary to lymphoproliferative diseases versus solid tumors (4 out of 19 vs 2 out of 18, respectively). We found seven heterozygous FANC variants, including two FANCA (L6F and 590T), three FANC2D (T1376A, P2565 and M1023V), one FANCJ (I364V) and one FANCC (L36F) (Table 2). There were no differences in the time between primary cytotoxic treatment and t-MN diagnosis in carriers of FA variant versus wild-type patients (median, 72 vs 69 months). Six variants were novel, according to the NCBI and Cosmic databases, whereas the FANCA L6F had been previously described in the 1000 Genome project (www.1000genomes.org) and reported in the UCSC Genome Browser in the transcript variant 2 of FANCA mRNA (uc002fow.1). This same variation has been functionally demonstrated as SNV in the 5’ UTR of NCBI Reference Assembly (rs189841793).

To determine whether FANC genetic variants were somatically acquired in t-MN patients, germline material was screened in five patients for whom control tissues were available. The FANC mutation was germline in all cases (5 confirmed in 37 t-MN patients, 13.5%) (Table 2). As a control, the frequency of FANC variant in t-MN was compared with that of 24 dnAML patients, studied using whole-exome-sequencing. We found that 3 out of 24 patients (12.5%) were carriers of a germline FA variant (1 FANCA, 1 FANCL and 1 FANCI). This translates into a similar prevalence of FA SNV in t-MN and dnAML. Since SNV in FA genes seem frequent both in dnAML and in t-MN, we suggest that these variants may have a role as risk factors in the development of myeloid neoplasms.

As all FANC variants were novel, further studies will be necessary to clarify the functional impact of these variants on the gene product and DNA damage repair. According to the Polyphen-2 database (genetics.bwh.harvard.edu) five out of eight FA variants were defined probably or possibly damaging DNA repair (Supplementary Table 2). Functional studies using constructs including the mutated sequences may help to answer this question.13

Our data indicate that heterozygous carriers of FA variants may have increased susceptibility to environmental carcinogens and to the DNA-damaging action of cytotoxic therapy used to treat primary tumors, leading to de novo or secondary leukemogenesis. In this line, a trend towards higher DEB-induced chromosome breakage and an increased release of fragmented DNA after exposure to X-irradiation have been reported in FA heterozygotes relative to controls.14

We have previously reported that t-MN secondary to lymphoproliferative diseases were characterized by a very low frequency or absence of epigenetic and splicesome gene mutations, compared to t-MN following solid tumors.15 As the frequency of FA germline variants in this study did not appear to be different between lymphoproliferative neoplasms and breast cancer and between de novo and t-MN, the probable functional role of these variants in carcinogenesis does not appear to be restricted to a specific type of primary cancer or its treatment.

In the near future, we might have to revise our concept of genetic susceptibility to AML, taking into account not only recurrent genetic variants, such as polymorphisms, but also rare individual germline variants in critical genes.

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

ACKNOWLEDGEMENTS
This work was supported by grants from Associazione Italiana Ricerca sul Cancro (AIRC) and FIRC (RBAI11TF72). We acknowledge L Pagano and S Sica, for providing patient samples, and G Neri for helpful comments on the manuscript.

MT Voso1,2, E Fabiani1, Z Zang3, F Lanich1, G Falconi1, A Padella4, M Martini5, S Li Zhang5, R Santangelo6, LM Larocca7, M Criscuolo7, A La Brocca1, I Cuticchae6, S Rozen6, G Simonetti7, M Manfrini1, G Martinelli1, S Hohaus1, G Leone1, P Tan1 and DG Tenen8

1Department of Hematology, Università Cattolica Sacro Cuore, Rome, Italy; 2Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy;
REFERENCES

1 Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008; 22: 240–248.

2 Leone G, Fianchi L, Voso MT. Therapy-related myeloid neoplasms. Curr Opin Oncol 2011; 23: 672–680.

3 Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998; 95: 13176–13181.

4 Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Uike N et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000; 6: 4091–4095.

5 Ellis NA, Huo D, Yildiz O, Worilllow LJ, Banerjee M, Le Beau MM et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008; 112: 741–749.

6 Fabiani E, Fianchi L, Falconi G, Boncompagni R, Criscuolo M, Guidi F et al. The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes. Leuk Lymphoma 2014; 55: 1538–1543.

7 Walden H, Deans AJ. The Fanconi anemia DNA repair pathway: structural and functional insights into a complex disorder. Annu Rev Biophys 2014; 43: 257–278.

8 Garaycoechea JI, Patel KJ. Why does the bone marrow fail in Fanconi anemia? Blood 2014; 123: 26–34.

9 Kee Y, D’Andrea AD. Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest 2012; 122: 3799–3806.

10 Schulz E, Valentin A, Ulz P, Beham-Schmid C, Lind K, Rupp V et al. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J Med Genet 2012; 49: 422–428.

11 Offman J, Gascoigne K, Bristow F, Macpherson P, Bignami M, Casorelli I et al. Repeated sequences in CASPASE-5 and FANCD2 but not NF1 are targets for mutation in microsatellite-unstable acute leukemia/myelodysplastic syndrome. Mol Cancer Res 2005; 3: 251–260.

12 Tischkowitz MD, Morgan NV, Grimwade D, Eddy C, Ball S, Vorechovsky I et al. Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia 2004; 18: 420–425.

13 Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.

14 Djuzenova CS, Rothfuss A, Oppitz U, Speit G, Schindler D, Hoehn H et al. Response to X-irradiation of Fanconi anemia homozygous and heterozygous cells assessed by the single-cell gel electrophoresis (comet) assay. Lab Invest 2001; 81: 185–192.

15 Voso MT, Fabiani E, Fianchi L, Falconi G, Criscuolo M, Santangelo R et al. Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia 2013; 27: 982–985.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Supplementary Information accompanies this paper on Blood Cancer Journal website (http://www.nature.com/bcj)